ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Integrin alpha V beta 3

Integrin alpha V beta 3

概要

Name:Integrin alpha-V/beta-3
Target Synonym:Integrin alphaVbeta3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:22
Lastest Research Phase:Phase 3 Clinical

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

IT3-H82W9-ELISA
 Integrin alpha V beta 3 ELISA

Immobilized Human Vitronectin at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB3 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT3-H82W9) with a linear range of 0.039-2.5 μg/mL (QC tested).

IT3-R52E2-MALS-HPLC
Integrin alpha V beta 3 MALS images

The purity of Rat ITGAV&ITGB3 Heterodimer, His Tag&Tag Free (Cat. No. IT3-R52E2) is more than 85% and the molecular weight of this protein is around 210-240kDa verified by SEC-MALS.

Synonym Name

Integrin alpha V beta 3,ITGAV&ITGB3

Background

Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Also, Integrin alpha-V/beta-3 acts as a receptor for herpes virus 8/HHV-8, coxsackievirus A9, Hantaan virus, cytomegalovirus/HHV-5, human metapneumovirus, human parechovirus 1 and west nile virus. Furthermore, in case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
(68)Ga-RGD Phase 1 Clinical Peking Union Medical College Hospital Keloid Details
Antiangiotide HM-3; IIM-3 Phase 1 Clinical Inner Mongolia Tianqi Pharmaceutical Group Co Ltd, China Pharmaceutical University Liver Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
MK-0429 MK-429; MK-0429; L-000845704 Merck Sharp & Dohme Corp Details
Pagantangentide Phase 1 Clinical Nanjing Anji Biological Technology Co Ltd, Jiangsu Aotexin Biomedical Technology Co Ltd, China Pharmaceutical University Arthritis, Rheumatoid; Rheumatic Diseases Details
IDL-2965 IDL-2965 Phase 2 Clinical Indalo Therapeutics Inc Non-alcoholic Fatty Liver Disease; Idiopathic Pulmonary Fibrosis Details
ProAgio Phase 1 Clinical National Cancer Institute Solid tumours; Pancreatic Neoplasms Details
68Ga-NOTA-3PTATE-RGD 68Ga-NOTA-3PTATE-RGD; 68Ga-NOTA-3P-TATE-RGD Phase 1 Clinical Peking Union Medical College Hospital Neuroendocrine Tumors; Lung Neoplasms Details
99mTc-3PRGD2 99mTc-3PRGD2 Phase 3 Clinical Peking University Lymphatic Metastasis; Lung Neoplasms Details
68Ga-NOTA-BBN-RGD 68Ga-NOTA-BBN-RGD Phase 1 Clinical Peking Union Medical College Hospital Breast Neoplasms; Prostatic Neoplasms Details
Alfatide[18F] 18F-AlF-NOTA-PRGD2; 18F-alfatide; alfatide II; AlF-NOTA-PRGD2-[18F] Phase 3 Clinical Jiangsu Smk Pharmaceutical Co Ltd, Taizhou Kairui Pharmaceutical Technology Co Ltd Carcinoma, Bronchogenic; Head and Neck Neoplasms; Neoplasms; Soft Tissue Neoplasms; Contrast agents; Breast Neoplasms; Lymphoma Details
BGC-0222 BGC0222; BGC-0222 Phase 1 Clinical Gaorui Yaoye (Beijing) Technologies Co Ltd, Brightgene Bio-Medical Technology Co Ltd Solid tumours Details
Ga-68 NODAGA-RGD [68Ga]Theranost; Theranost 68Ga-RGD Phase 1 Clinical Advanced Imaging Projects, Zentralklinik Bad Berka, National Cancer Institute Neovascularization, Pathologic; Prostatic Neoplasms; Contrast agents; Breast Neoplasms; Brain Neoplasms; Lung Neoplasms Details
fb-PMT NP-100; NP-751 Phase 1 Clinical NanoPharmaceuticals LLC Glioma Details
OTT-166 OTT-166 Phase 2 Clinical OcuTerra Therapeutics Inc Diabetic Retinopathy Details
[68Ga]-FF58 Phase 1 Clinical Novartis Pharma Ag Stomach Neoplasms; Esophageal Neoplasms; Glioblastoma; Brain Neoplasms; Carcinoma, Pancreatic Ductal Details

This web search service is supported by Google Inc.

totopphone